摘要 |
<p>Co-administration of cisplatin with a pharmaceutically acceptable form of 2,2'-dithio-bis(ethanesulfonate) reduces the nephrotoxicity and myelosuppression of cisplatin and potentiates its anti-tumor action. Preferably the cisplatin and sulfonate are formulated as a composition, especially a sterile injectable solution containing chloride ions and sodium and hydrogen cations.</p> |